Caldera Therapeutics

Caldera Therapeutics is a Boston-based biotechnology company dedicated to developing innovative therapeutic solutions for inflammatory bowel disease and other immunologic conditions, focusing on its bispecific antibody product, CLD-423. Founded in 2025, Caldera Therapeutics specializes in advancing treatments for inflammatory diseases. The company has secured a total of USD 35. 00 mn in Series A funding led by Omega Funds, with participation from other investors Wellington Management and Janus Henderson Investors.

The founder's history and prior ventures are not publicly detailed, but the company is positioned strategically in Boston, US, for its operations. Caldera Therapeutics focuses on developing innovative therapeutic solutions for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, centering on its flagship product, the bispecific antibody CLD-423. This first-in-class therapeutic targets the clinically validated IL-23p19 and TL1A pathways, combining these two potent autoimmune targets into a single molecule. The primary end use cases for CLD-423 revolve around improving treatment efficacy for patients suffering from IBD, particularly where existing single-target therapies have reached an efficacy ceiling.

Currently, the Phase 1 clinical trial of CLD-423 is ongoing, which signifies its recent introduction into the clinical testing phase. Caldera's customer base primarily includes healthcare providers and institutions involved in treating inflammatory diseases, with potential markets extending to North America and Europe, where there is a high prevalence of IBD. Caldera Therapeutics is in the clinical stage of its product offering and has recently secured USD 35. 00 mn in funding, which supports the advancement of its bispecific antibody CLD-423 through clinical trials.

Given the nature of the biotechnology sector, revenue generation is expected to primarily occur through partnerships with healthcare organizations and potentially through licensing agreements with pharmaceutical companies upon successful clinical validation of its product. The structure of transactions may involve B2B partnerships with hospitals and healthcare providers who would integrate CLD-423 into their treatment protocols. Pricing for the bispecific antibody is anticipated to be determined in relation to the therapeutic value and outcomes achieved, with no specific pricing plans disclosed at this time. The company's revenue model is designed to capitalize on the increasing demand for advanced therapeutic solutions in the treatment of chronic diseases such as IBD.

Caldera Therapeutics plans to leverage its recent Series A funding of USD 35. 00 mn to advance the clinical development of CLD-423 and explore further therapeutic candidates targeting inflammatory diseases. The company aims to expand its clinical trials and plans to target the North American and European markets for growth by 2026. The funding will facilitate critical research and development efforts, enabling the company to enhance its product pipeline and foster strategic partnerships with healthcare providers.